LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Aprile 2024 - 12:28AM
Business Wire
LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today
announced that a majority of the independent members of LENSAR’s
board of directors granted three newly-hired non-executive
employees stock options to purchase an aggregate of 1,425 shares of
the Company’s common stock. The options were granted as of April 1,
2024, as inducements material to each employee entering into
employment with the Company. The options were granted in accordance
with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $3.38 per share, which is
equal to the closing price of the Company’s common stock on the
grant date. The options vest as to 25% of the total amount of the
award on the one-year anniversary of the grant date and in
thirty-six substantially equal monthly installments thereafter,
subject to the new employee’s continued service with the company.
Each stock option has a 10-year term. The options are subject to
the terms and conditions of LENSAR’s 2024 Employment Inducement
Incentive Award Plan and a stock option agreement covering the
grant.
About LENSAR
LENSAR is a commercial-stage medical device company focused on
designing, developing, and marketing advanced systems for the
treatment of cataracts and the management of astigmatism as an
integral aspect of the cataract procedure. LENSAR has developed its
next-generation ALLY® Adaptive Cataract Treatment System, the first
platform to integrate proprietary imaging and software, with an
extremely fast dual-pulse femtosecond laser in a compact, highly
ergonomic system. ALLY is designed to transform premium cataract
surgery by utilizing LENSAR’s advanced technologies with the
ability to perform the entire procedure in an operating room or
in-office surgical suite, delivering operational efficiencies and
reduced overhead. ALLY includes LENSAR’s proprietary Streamline®
software technology, designed to guide surgeons to achieve better
outcomes.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240401083139/en/
Thomas R. Staab, II, CFO ir.contact@lensar.com
Lee Roth / Cameron Radinovic Burns McClellan for LENSAR
lroth@burnsmc.com / cradinovic@burnsmc.com
Grafico Azioni LENSAR (NASDAQ:LNSR)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni LENSAR (NASDAQ:LNSR)
Storico
Da Gen 2024 a Gen 2025